News | March 11, 2008| Cristen C. Bolan

Avoid Interventional Overload with ACC FastPass

Cristen C. Bolan, Editor, Diagnostic & Invasive Cardiology

This may be the Red Bull of interventional cardiology sessions, since The Society of Cardiovascular Angiography and Interventions (SCAI) and ACC’s Innovation in Intervention: i2 Summit joined forces to form the “SCAI-ACCi2” meeting.
You might need a few energy drinks to keep up with this interventional power pack, which runs concomitantly with ACC.08. Sessions will feature live case transmissions, highlight emerging technologies, provide case reviews on IVUS, left main, CTO, valvular and structural procedures, bifurcation and endovascular procedures, and opinions can be voiced in debates covering COURAGE, PCI versus CABG, DES selection, embolic protection, vulnerable plaque, IIb/IIIa inhibitors, PFO closure for stroke, elective PCI and carotid stenting in asymptomatic patients.
But before your heart starts racing from either the caffeine or in anticipation of all there is to see and do, conference organizers promise to recreate that same intimate feel and collegial interaction of the SCAI meeting.
Just in case, Diagnostic & Invasive Cardiology will help control information overload by streamlining the data for you on our ACC FastPass found at www.DIcardiology.net. ACC FastPass delivers updates on case reviews and debates, keynotes and new technology roll outs before, during and after ACC, and presents it to you in a more manageable package, so you’ll have energy enough to get all of the info you need.

Related Content

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents | November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init